Cindy  Tahl net worth and biography

Cindy Tahl Biography and Net Worth

General Counsel of Fate Therapeutics
Cindy Tahl is General Counsel at Fate Therapeutics and is serving as a key advisor in day to day operations, providing legal advice and counsel for all functions of the business and overseeing company compliance. Ms. Tahl also directs the development and expansion of the Company’s IP portfolio. Prior to joining Fate, Ms. Tahl was a technology transactions attorney at Wilson Sonsini Goodrich & Rosati, P.C., and practiced intellectual property law in the New York office of Kenyon & Kenyon, LLP. Ms. Tahl has worked extensively with biotechnology companies at all stages of growth, representing clients in numerous corporate transactions and executing patent strategy to advance corporate goals. Ms. Tahl received a J.D. from Boston College Law School and a B.S. in biology from the University of California, San Diego. She is admitted to the state bars of California and New York, and is registered to practice as a patent attorney before the U.S. Patent and Trademark Office.

What is Cindy Tahl's net worth?

The estimated net worth of Cindy Tahl is at least $1.04 million as of January 9th, 2024. Ms. Tahl owns 142,361 shares of Fate Therapeutics stock worth more than $1,044,930 as of March 29th. This net worth estimate does not reflect any other assets that Ms. Tahl may own. Additionally, Ms. Tahl receives an annual salary of $455,000.00 as General Counsel at Fate Therapeutics. Learn More about Cindy Tahl's net worth.

How old is Cindy Tahl?

Ms. Tahl is currently 51 years old. There are 3 older executives and no younger executives at Fate Therapeutics. The oldest executive at Fate Therapeutics is Mr. J. Scott Wolchko, Founder, CEO, President & Director, who is 54 years old. Learn More on Cindy Tahl's age.

What is Cindy Tahl's salary?

As the General Counsel of Fate Therapeutics, Inc., Ms. Tahl earns $455,000.00 per year. The highest earning executive at Fate Therapeutics is Mr. J. Scott Wolchko, Founder, CEO, President & Director, who commands a salary of $645,000.00 per year. Learn More on Cindy Tahl's salary.

How do I contact Cindy Tahl?

The corporate mailing address for Ms. Tahl and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]. Learn More on Cindy Tahl's contact information.

Has Cindy Tahl been buying or selling shares of Fate Therapeutics?

In the last ninety days, Cindy Tahl has sold $47,519.38 in shares of Fate Therapeutics stock. Most recently, Cindy Tahl sold 10,874 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a transaction totalling $47,519.38. Following the completion of the sale, the general counsel now directly owns 142,361 shares of the company's stock, valued at $622,117.57. Learn More on Cindy Tahl's trading history.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, Fate Therapeutics insiders bought shares 3 times. They purchased a total of 90,330 shares worth more than $440,023.60. In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 65,791 shares worth more than $295,027.59. The most recent insider tranaction occured on January, 29th when CFO Edward J Dulac III sold 1,849 shares worth more than $9,245.00. Insiders at Fate Therapeutics own 5.0% of the company. Learn More about insider trades at Fate Therapeutics.

Information on this page was last updated on 1/29/2024.

Cindy Tahl Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/9/2024Sell10,874$4.37$47,519.38142,361View SEC Filing Icon  
1/10/2023Sell11,553$5.24$60,537.72177,598View SEC Filing Icon  
4/1/2022Sell25,000$38.85$971,250.00189,151View SEC Filing Icon  
1/10/2022Sell7,738$46.43$359,275.34View SEC Filing Icon  
10/1/2021Sell50,000$58.83$2,941,500.00View SEC Filing Icon  
4/1/2021Sell30,000$83.81$2,514,300.00136,197View SEC Filing Icon  
1/19/2021Sell35,000$114.76$4,016,600.00125,035View SEC Filing Icon  
1/11/2021Sell9,483$114.94$1,089,976.0296,763View SEC Filing Icon  
1/8/2021Sell6,229$117.10$729,415.9096,763View SEC Filing Icon  
10/16/2020Sell29,199$50.25$1,467,249.75128,717View SEC Filing Icon  
10/15/2019Sell10,200$14.24$145,248.00View SEC Filing Icon  
3/1/2019Sell25,000$16.15$403,750.00115,418View SEC Filing Icon  
2/25/2019Sell25,000$16.07$401,750.00115,418View SEC Filing Icon  
1/7/2019Sell25,000$16.00$400,000.0047,426View SEC Filing Icon  
10/16/2017Sell8,091$3.85$31,150.35View SEC Filing Icon  
See Full Table

Cindy Tahl Buying and Selling Activity at Fate Therapeutics

This chart shows Cindy Tahl's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.34
Low: $7.23
High: $7.64

50 Day Range

MA: $6.70
Low: $4.53
High: $8.35

2 Week Range

Now: $7.34
Low: $1.63
High: $8.83

Volume

2,715,589 shs

Average Volume

2,728,520 shs

Market Capitalization

$728.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67